Recent Research Analysts’ Ratings Updates for Edwards Lifesciences (EW)

Several brokerages have updated their recommendations and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last few weeks:

• 12/16/2024 – Edwards Lifesciences was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating. They now have a $90.00 price target on the stock, up previously from $82.00.
• 12/11/2024 – Edwards Lifesciences had its price target raised by analysts at Citigroup Inc. from $81.00 to $83.00. They now have a “buy” rating on the stock.
• 12/5/2024 – Edwards Lifesciences had its price target raised by analysts at Royal Bank of Canada from $80.00 to $85.00. They now have an “outperform” rating on the stock.
• 12/5/2024 – Edwards Lifesciences had its “hold” rating reaffirmed by analysts at Truist Financial Co.. They now have a $78.00 price target on the stock, up previously from $70.00.
• 12/5/2024 – Edwards Lifesciences had its price target raised by analysts at Stifel Nicolaus from $70.00 to $75.00. They now have a “hold” rating on the stock.
• 12/5/2024 – Edwards Lifesciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $63.00 to $68.00. They now have a “hold” rating on the stock.
• 12/5/2024 – Edwards Lifesciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $81.00 to $90.00. They now have a “buy” rating on the stock.
• 12/2/2024 – Edwards Lifesciences had its price target raised by analysts at Barclays PLC from $85.00 to $88.00. They now have an “overweight” rating on the stock.
• 11/27/2024 – Edwards Lifesciences had its price target raised by analysts at Royal Bank of Canada from $75.00 to $80.00. They now have an “outperform” rating on the stock.
• 10/30/2024 – Edwards Lifesciences was downgraded by analysts at Daiwa America from a “strong-buy” rating to a “hold” rating.
• 10/28/2024 – Edwards Lifesciences was upgraded by analysts at Sanford C. Bernstein from a “strong sell” rating to a “hold” rating.
• 10/25/2024 – Edwards Lifesciences had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $78.00. They now have a “neutral” rating on the stock.
• 10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Piper Sandler from $73.00 to $70.00. They now have a “neutral” rating on the stock.
• 10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Robert W. Baird from $73.00 to $68.00. They now have a “neutral” rating on the stock.
• 10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Canaccord Genuity Group Inc. from $66.00 to $63.00. They now have a “hold” rating on the stock.
• 10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Truist Financial Co. from $71.00 to $70.00. They now have a “hold” rating on the stock.

Edwards Lifesciences Trading Down 0.2 %

NYSE EW traded down $0.15 on Monday, reaching $74.66. The company had a trading volume of 2,616,089 shares, compared to its average volume of 4,717,468. The firm has a market cap of $44.03 billion, a price-to-earnings ratio of 10.77, a P/E/G ratio of 3.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The business has a 50 day moving average of $70.06 and a two-hundred day moving average of $73.52.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.59 earnings per share. Analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,500 shares of company stock worth $2,508,350. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently added to or reduced their stakes in EW. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $32,000. Avior Wealth Management LLC increased its position in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. HHM Wealth Advisors LLC bought a new position in Edwards Lifesciences in the 2nd quarter valued at $55,000. Finally, Peoples Bank KS purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $40,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.